OSTIFEN- carprofen tablet, chewable

País: Estados Unidos

Língua: inglês

Origem: NLM (National Library of Medicine)

Ingredientes ativos:

carprofen (UNII: FFL0D546HO) (carprofen - UNII:FFL0D546HO)

Disponível em:

MWI/VetOne

DCI (Denominação Comum Internacional):

carprofen

Composição:

carprofen 25 mg

Via de administração:

ORAL

Tipo de prescrição:

PRESCRIPTION

Indicações terapêuticas:

OstiFen is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs. OstiFen should not be used in dogs exhibiting previous hypersensitivity to carprofen.

Resumo do produto:

OstiFen chewable tablets are scored, and contain 25 mg, 75 mg, or 100 mg of carprofen per tablet. Each tablet size is packaged in bottles containing 30, 60, or 180 tablets.

Status de autorização:

Abbreviated New Animal Drug Application

Características técnicas

OSTIFEN- CARPROFEN TABLET, CHEWABLE
MWI/VETONE
----------
Approved by FDA under ANADA # 200-595
OSTIFEN
(CARPROFEN)
CHEWABLE TABLETS
_NON-STEROIDAL ANTI-INFLAMMATORY DRUG_
FOR ORAL USE IN DOGS ONLY
CAUTION:
Federal law restricts this drug to use by or on the order of a
licensed veterinarian.
DESCRIPTION:
OstiFen™ (carprofen) is a non-steroidal anti-inflammatory drug
(NSAID) of the propionic
acid class that includes ibuprofen, naproxen, and ketoprofen.
Carprofen is the
nonproprietary designation for a substituted carbazole,
6-chloro-α-methyl-9H-carbazole-
2-acetic acid. The empirical formula is C
H
CINO and the molecular weight is 273.72.
The chemical structure of carprofen is:
Carprofen is a white, crystalline compound. It is freely soluble in
ethanol, but practically
insoluble in water at 25ºC.
CLINICAL PHARMACOLOGY:
Carprofen is a non-narcotic, non-steroidal anti-inflammatory agent
with characteristic
analgesic and antipyretic activity approximately equipotent to
indomethacin in animal
models.
The mechanism of action of carprofen, like that of other NSAIDs, is
believed to be
associated with the inhibition of cyclooxygenase activity. Two unique
cyclooxygenases
have been described in mammals.
The constitutive cyclooxygenase, COX-1,
synthesizes prostaglandins necessary for normal gastrointestinal and
renal function.
The inducible cyclooxygenase, COX-2, generates prostaglandins involved
in
inflammation. Inhibition of COX-1 is thought to be associated with
gastrointestinal and
renal toxicity while inhibition of COX-2 provides anti-inflammatory
activity. The specificity
of a particular NSAID for COX-2 versus COX-1 may vary from species to
species.
In an
_in vitro_ study using canine cell cultures, carprofen demonstrated
selective inhibition of
™
15
12
2
1
2
3
4
COX-2 versus COX-1.
Clinical relevance of these data has not been shown. Carprofen
has also been shown to inhibit the release of several prostaglandins
in two inflammatory
cell systems: rat polymorphonuclear leukocytes (PMN) and human
rheumatoid synovial